利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

118 条记录 (耗时 0.048 秒)

    INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
    62.
    发明申请
    INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES 有权
    用于医疗用途的衍生衍生物及其用途

    公开(公告)号：US20120015972A1

    公开(公告)日：2012-01-19

    申请号：US13259621

    申请日：2010-03-30

    申请人： Kazuo Shimizu ,  Masato Iizuka ,  Yasushi Takigawa

    发明人： Kazuo Shimizu ,  Masato Iizuka ,  Yasushi Takigawa

    IPC分类号： A61K31/437 ,  A61P13/12 ,  A61P19/02 ,  C07D471/04

    CPC分类号： C07D471/04

    摘要： The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level and the like. That is, the present invention relates to indolizine derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, salts thereof or the like. In the formula, ring U represents aryl or heteroaryl; R1 represents halogen, a hydroxy group or the like; R2 represents halogen, a hydroxy group, alkyl, alkoxy, alkyl substituted by fluorine, alkoxy substituted by fluorine or the like; m represents a number from 0 to 2; n represents a number from 0 to 3; and R3 represents hydrogen, fluorine or the like.

    摘要翻译： 本发明提供了可用作预防或治疗与血清尿酸水平异常等有关的疾病的药剂的化合物。 也就是说，本发明涉及具有黄嘌呤氧化酶抑制活性的由下式（I）表示的中氮茚衍生物，可用作预防或治疗与血清尿酸水平异常有关的疾病，其前药，其盐或 类似。 在该式中，环U表示芳基或杂芳基; R1表示卤素，羟基等; R 2表示卤素，羟基，烷基，烷氧基，被氟取代的烷基，被氟取代的烷氧基等; m表示0〜2的数; n表示0〜3的数; R 3表示氢，氟等。

    Method for separation and recovery of noble metals
    64.
    发明授权
    Method for separation and recovery of noble metals 有权
    贵金属分离回收方法

    公开(公告)号：US07857888B2

    公开(公告)日：2010-12-28

    申请号：US12160852

    申请日：2007-01-12

    申请人： Kazuhiro Niisawa ,  Kazuo Shimizu ,  Tadashi Nozaki

    发明人： Kazuhiro Niisawa ,  Kazuo Shimizu ,  Tadashi Nozaki

    IPC分类号： C22B3/24

    CPC分类号： C22B11/04 ,  B01D15/1871 ,  B01D15/265 ,  B01D15/426 ,  B01J20/24 ,  B01J2220/4825 ,  C22B3/10 ,  C22B3/24 ,  C22B11/042 ,  C22B11/048 ,  C22B11/06 ,  Y02P10/214 ,  Y02P10/234

    摘要： A method for separation and recovery of noble metals which makes it possible to isolate noble metal components efficiently by easy operation, that is, a method which comprises passing a solution of metals in hydrochloric acid prepared by treating a metal material with hydrochloric acid through the first cellulose column, eluting through development the noble metal component adsorbed on the cellulose with a hydrochloric acid/2-propanone mixture to obtain a fraction containing light platinum-group metals and a fraction containing heavy platinum-group metals and gold, separating the former fraction with the above mixture into fractions containing palladium, ruthenium and rhodium respectively, passing the fraction containing heavy platinum-group metals and gold through the second cellulose column to made them adsorbed on the cellulose, eluting them from the cellulose with a hydrochloric acid/1-butanol mixture to obtain fractions containing gold, osmium, iridium and platinum respectively, and recovering the noble metals from the fractions containing them respectively as simple substances.

    摘要翻译： 贵金属的分离回收方法，能够容易地使贵金属成分有效地分离，也就是将金属溶液中的金属在盐酸中的溶液通过第1次 纤维素柱，通过用盐酸/ 2-丙酮混合物显影吸附在纤维素上的贵金属组分，得到含有轻铂族金属的部分和含有重铂族金属和金的部分，将前一部分与 将上述混合物分别含有含有钯，钌和铑的级分，使含有重铂族金属和金的级分通过第二纤维素柱，使其吸附在纤维素上，用盐酸/ 1-丁醇从纤维素中洗脱出来 混合物以分别得到含有金，锇，铱和铂的级分，a 并从分别含有它们的级分中回收贵金属作为简单物质。

    Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
    66.
    发明授权
    Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof 有权
    吡唑衍生物，含有该吡唑衍生物的药物组合物，其医药用途及其生产用中间体

    公开(公告)号：US07635684B2

    公开(公告)日：2009-12-22

    申请号：US10525197

    申请日：2003-08-21

    申请人： Nobuhiko Fushimi ,  Kazuo Shimizu ,  Shigeru Yonekubo ,  Hirotaka Teranishi ,  Masaki Tomae ,  Masayuki Isaji

    发明人： Nobuhiko Fushimi ,  Kazuo Shimizu ,  Shigeru Yonekubo ,  Hirotaka Teranishi ,  Masaki Tomae ,  Masayuki Isaji

    IPC分类号： A61K31/7028 ,  A01N43/56 ,  C07H17/02 ,  C07D231/12

    CPC分类号： A61K38/185 ,  A61K31/00 ,  A61K31/10 ,  A61K31/205 ,  A61K31/37 ,  A61K31/4166 ,  A61K31/7056 ,  A61K31/7072 ,  A61K31/737 ,  A61K38/1858 ,  A61K38/28 ,  A61K45/06 ,  C07H17/02 ,  A61K2300/00

    摘要： The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents —RB, —CORC etc. in which RB represents an optionally substituted C1-6 alkyl group etc.; and RC represents an optionally substituted C1-6 alkyl group etc.; R4 represents H, an optionally substituted C1-6 alkyl group etc.; and R3, R5 and R6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

    摘要翻译： 本发明提供由以下通式表示的吡唑衍生物：其中R1表示H，任选取代的C 1-6烷基等; Q和T之一表示由通式表示的基团或由通式表示的基团：而另一个表示任选取代的C 1-6烷基等; R2表示H，卤素原子，OH，任意取代的C 1-6烷基等; X表示单键，O或S; Y表示任选取代的C 1-6亚烷基等; Z表示-RB，-CORC等，其中RB表示任选取代的C 1-6烷基等; 并且RC表示任选取代的C 1-6烷基等; R4代表H，任选取代的C 1-6烷基等; R3，R5和R6表示H，卤素原子等，其药学上可接受的盐或其前药，其在人SGLT1中表现出优异的抑制活性，并且可用作预防或治疗与高血糖相关的疾病的药剂，例如 糖尿病，葡萄糖耐量减低，空腹血糖受损，糖尿病并发症或肥胖症，以及与半乳糖水平升高相关的疾病，以及包含其的药物组合物，其制药用途及其生产用中间体。

    PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF
    67.
    发明申请
    PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF 有权
    吡唑衍生物，含有它们的药物组合物，药物用途及其生产中间体

    公开(公告)号：US20090203633A1

    公开(公告)日：2009-08-13

    申请号：US12421236

    申请日：2009-04-09

    申请人： Nobuhiko Fushimi ,  Kazuo Shimizu ,  Shigeru Yonekubo ,  Hirotaka Teranishi ,  Masaki Tomae

    发明人： Nobuhiko Fushimi ,  Kazuo Shimizu ,  Shigeru Yonekubo ,  Hirotaka Teranishi ,  Masaki Tomae

    IPC分类号： A61K31/7056

    CPC分类号： A61K38/185 ,  A61K31/00 ,  A61K31/10 ,  A61K31/205 ,  A61K31/37 ,  A61K31/4166 ,  A61K31/7056 ,  A61K31/7072 ,  A61K31/737 ,  A61K38/1858 ,  A61K38/28 ,  A61K45/06 ,  C07H17/02 ,  A61K2300/00

    摘要： The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents —RB, —CORC etc. in which RB represents an optionally substituted C1-6 alkyl group etc.; and RC represents an optionally substituted C1-6 alkyl group etc.; R4 represents H, an optionally substituted C1-6 alkyl group etc.; and R3, R5 and R6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

    摘要翻译： 本发明提供由以下通式表示的吡唑衍生物：其中R1表示H，任选取代的C 1-6烷基等; Q和T之一表示由通式表示的基团或由通式表示的基团：而另一个表示任选取代的C 1-6烷基等; R2表示H，卤素原子，OH，任意取代的C 1-6烷基等; X表示单键，O或S; Y表示任选取代的C 1-6亚烷基等; Z表示-RB，-CORC等，其中RB表示任选取代的C 1-6烷基等; 并且RC表示任选取代的C 1-6烷基等; R4代表H，任选取代的C 1-6烷基等; R3，R5和R6表示H，卤素原子等，其药学上可接受的盐或其前药，其在人SGLT1中表现出优异的抑制活性，并且可用作预防或治疗与高血糖相关的疾病的药剂，例如 糖尿病，葡萄糖耐量减低，空腹血糖受损，糖尿病并发症或肥胖症，以及与半乳糖水平升高相关的疾病，以及包含其的药物组合物，其制药用途及其生产用中间体。

    IMAGING DEVICE AND DISPLAY APPARATUS
    68.
    发明申请
    IMAGING DEVICE AND DISPLAY APPARATUS 审中-公开
    成像装置和显示装置

    公开(公告)号：US20090102768A1

    公开(公告)日：2009-04-23

    申请号：US12245039

    申请日：2008-10-03

    申请人： Kazuo Shimizu

    发明人： Kazuo Shimizu

    IPC分类号： G02F1/1335

    CPC分类号： H04N9/045 ,  H04N2209/045

    摘要： An imaging device includes on-chip color filters in four or more colors, and these on-chip color filters are arranged two-dimensionally in a mosaic form. Focusing on only on-chip color filters of the same color from among the on-chip color filters, these on-chip color filters are arranged such that an arrangement pitch between adjacent on-chip color filters is substantially constant. The arrangement pitch can also be made substantially identical among on-chip color filters of different colors.

    摘要翻译： 成像装置包括四种或更多种颜色的片上滤色器，并且这些片上滤色器以马赛克形式二维布置。 这些片上滤色器仅专注于片上滤色器中相同颜色的片上滤色器，以使得相邻的片上滤色器之间的布置间距基本恒定。 布置间距也可以在不同颜色的片上滤色器之间基本相同。

    NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS
    69.
    发明申请
    NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS 有权
    含氮化合物衍生物，含有衍生物的药物组合物及其作为药物的用途

    公开(公告)号：US20080188426A1

    公开(公告)日：2008-08-07

    申请号：US12032411

    申请日：2008-02-15

    申请人： Nobuhiko FUSHIMI ,  Hirotaka Teranishi ,  Kazuo Shimizu ,  Shigeru Yonekubo ,  Fumiaki Ito ,  Masayuki ISAJI

    发明人： Nobuhiko FUSHIMI ,  Hirotaka Teranishi ,  Kazuo Shimizu ,  Shigeru Yonekubo ,  Fumiaki Ito ,  Masayuki ISAJI

    IPC分类号： A61K31/7056 ,  C07H19/01 ,  A61P3/10

    CPC分类号： A61K31/7056 ,  A61K31/706 ,  C07H17/02

    摘要： The present invention provides nitrogen-containing fused-ring derivatives represented by the following general formula, or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, in the formula R1 represent H, an optionally substituted alkyl group, an alkenyl group, etc.; R2 represent H, a halogen atom or an alkyl group; R3 and R4 represent H, OH, a halogen atom, an optionally substituted alkyl group, etc.; Y represents CH or N; Q represents alkylene, alkenylene, etc.; ring A represents an aryl group or a heteroaryl group; G represents a group represented by the following general formula (G-1) or (G-2) (in which E1 represents H, F or OH; and E2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

    摘要翻译： 本发明提供由以下通式表示的含氮稠环衍生物或其药学上可接受的盐或其前药，其在人SGLT中表现出优异的抑制活性，并且可用作预防或治疗疾病的药剂 与糖尿病，餐后高血糖症，葡萄糖耐量降低，糖尿病并发症或肥胖症等高血糖相关的R 1表示H，任选取代的烷基，烯基等; R 2表示H，卤素原子或烷基; R 3和R 4代表H，OH，卤素原子，任选取代的烷基等; Y表示CH或N; Q表示亚烷基，亚烯基等; 环A表示芳基或杂芳基; G表示由以下通式（G-1）或（G-2）表示的基团（其中E H表示H，F或OH;以及E < 表示H，F，甲基等），以及含有它们的药物组合物及其药物用途。

    Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
    70.
    发明授权
    Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs 有权
    含氮稠环衍生物，含有衍生物的药物组合物及其作为药物的用途

    公开(公告)号：US07375113B2

    公开(公告)日：2008-05-20

    申请号：US10591757

    申请日：2005-03-03

    申请人： Nobuhiko Fushimi ,  Hirotaka Teranishi ,  Kazuo Shimizu ,  Shigeru Yonekubo ,  Fumiaki Ito ,  Masayuki Isaji

    发明人： Nobuhiko Fushimi ,  Hirotaka Teranishi ,  Kazuo Shimizu ,  Shigeru Yonekubo ,  Fumiaki Ito ,  Masayuki Isaji

    IPC分类号： A61K31/44 ,  A61K31/405 ,  A01N43/38 ,  C07D498/02 ,  C07D513/02

    CPC分类号： A61K31/7056 ,  A61K31/706 ,  C07H17/02

    摘要： The present invention provides nitrogen-containing fused-ring derivatives represented by the following general formula, or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, in the formula R1 represent H, an optionally substituted alkyl group, analkenyl group, etc.; R2 represent H, a halogen atom or an alkyl group; R3 and R4 represent H, OH, a halogen atom, an optionally substituted alkyl group, etc.; Y represents CH or N; Q represents alkylene, alkenylene, etc.; ring A represents an aryl group or a heteroaryl group; G represents a group represented by the following general formula (G-1) or (G-2) (in which E1 represents H, F or OH; and E2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof

    摘要翻译： 本发明提供由以下通式表示的含氮稠环衍生物或其药学上可接受的盐或其前药，其在人SGLT中表现出优异的抑制活性，并且可用作预防或治疗疾病的试剂 与糖尿病，餐后高血糖症，葡萄糖耐量降低，糖尿病并发症或肥胖症等高血糖相关，其中R 1表示H，任选取代的烷基，断链基等; R 2表示H，卤素原子或烷基; R 3和R 4代表H，OH，卤素原子，任选取代的烷基等; Y表示CH或N; Q表示亚烷基，亚烯基等; 环A表示芳基或杂芳基; G表示由以下通式（G-1）或（G-2）表示的基团（其中E H表示H，F或OH;以及E < 表示H，F，甲基等），以及含有它们的药物组合物及其药物用途